The DSMB's recommendation to continue the ASPIRE trial without modifications is a strong endorsement of the trial's safety profile. This news is likely to be viewed positively by investors as it suggests that the trial is proceeding as planned, which could potentially lead to successful outcomes and future regulatory approvals. The direct mention of Panbela and the specific nature of the news suggest a high relevance and importance to the company's stock price in the short term.